Correlation between the expression of TYK2 and STAT3 in non-functioning pituitary adenomas and invasiveness

doi:10.3877/cma.j.issn.2095-123X.2022.01.004

Abstract

Abstract:

Objective

To investigate the correlation between the expression of tyrosine kinase 2 (TYK2) and signal transducers and activators of transcription 3 (STAT3) in non-functioning pituitary adenoma (NFPA) and invasiveness.

Methods

Clinical data and surgical specimens of 24 patients with NFPA treated in our hospital from June 2020 to May 2021 were collected and divided into invasive and non-invasive NFPA groups based on their pre-operative imaging and intra-operative information, comprising 12 patients for each group. TYK2 and STAT3 expressions in the NFPA tissues of the two groups were measured by quantitative real-time polymerase chain reaction (qRT-PCR), immunohistochemistry (IHC) and Western blotting, and the correlation among their expressions in NFPA and invasiveness was analysed.

Results

The results of qRT-PCR, Western blot and immunohistochemistry showed that low TYK2 and high STAT3 expressed in the NFPA of the invasive group compared to the non-invasive group (P<0.05).

Conclusion

The expression of TYK2 in invasive NFPA is down-regulated and its low expression may be associated with NFPA invasiveness; The expression of STAT3 in invasive NFPA is up-regulated and its high expression may be associated with NFPA invasiveness.

Key words: Non-functioning pituitary adenoma, Tyrosine kinase 2, Signal transducers and activators of transcription 3, Invasiveness

Yasen Abudukadier, Tu Ba, Cheng Zhang, Tuoheti Maimaitiyiming, Xiaopeng Yang, Yonggang Wu. Correlation between the expression of TYK2 and STAT3 in non-functioning pituitary adenomas and invasiveness[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2022, 12(01): 27-31.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2022.01.004

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2022/V12/I01/27

Figures/Tables 4

References 17

[1]	Yu SY, Hong LC, Feng J, et al. Integrative proteomics and transcriptomics identify novel invasive-related biomarkers of non-functioning pituitary adenomas[J]. Tumour Biol, 2016, 37(7): 8923-8930.
[2]	Guo J, Wang Z, Miao Y, et al. A two-circRNA signature predicts tumour recurrence in clinical non-functioning pituitary adenoma[J]. Oncol Rep, 2019, 41(1): 113-124.
[3]	Fu P, He YS, Cen YC, et al. Microneurosurgery and subsequent gamma knife radiosurgery for functioning pituitary macroadenomas or giant adenomas: one institution's experience[J]. Clin Neurol Neurosurg, 2016, 145: 8-13.
[4]	杨昕，唐哲，张鹏,等. JAK/STAT信号通路在肺癌中的研究进展[J].中国肺癌杂志, 2019, 22(1): 45-51.
[5]	Bousoik E, Montazeri Aliabadi H. "Do we know Jack" about JAK? A closer look at JAK/STAT signaling pathway[J]. Front Oncol, 2018, 8: 287.
[6]	Wöss K, Simonović N, Strobl B, et al. TYK2: an upstream kinase of STATs in cancer[J]. Cancers (Basel), 2019, 11(11): 1728.
[7]	Wu P, Wu D, Zhao L, et al. Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis[J]. Oncotarget, 2016, 7(15): 19863-19883.
[8]	Owen KL, Brockwell NK, Parker BS. JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression[J]. Cancers (Basel), 2019, 11(12): 2002.
[9]	Borcherding DC, He K, Amin NV, et al. TYK2 in cancer metastases: genomic and proteomic discovery[J]. Cancers (Basel), 2021, 13(16): 4171.
[10]	Huynh J, Etemadi N, Hollande F, et al. The JAK/STAT3 axis: a comprehensive drug target for solid malignancies[J]. Semin Cancer Biol, 2017, 45: 13-22.
[11]	Ou A, Ott M, Fang D, et al. The role and therapeutic targeting of JAK/STAT signaling in glioblastoma[J]. Cancers (Basel), 2021, 13(3): 437.
[12]	Leitner NR, Witalisz-Siepracka A, Strobl B, et al. Tyrosine kinase 2-surveillant of tumours and bona fide oncogene[J]. Cytokine, 2017, 89: 209-218.
[13]	Sang QX, Man YG, Sung YM, et al. Non-receptor tyrosine kinase 2 reaches its lowest expression levels in human breast cancer during regional nodal metastasis[J]. Clin Exp Metastasis, 2012, 29(2): 143-153.
[14]	Feng J, Yu SY, Li CZ, et al. Integrative proteomics and transcriptomics revealed that activation of the IL-6R/JAK2/STAT3/MMP9 signaling pathway is correlated with invasion of pituitary null cell adenomas[J]. Mol Cell Endocrinol, 2016, 436: 195-203.
[15]	Shen X, Liu Q, Xu J, et al. Correlation between the expression of interleukin-6, STAT3, E-Cadherin and N-Cadherin protein and invasiveness in nonfunctional pituitary adenomas[J]. J Neurol Surg B Skull Base, 2021, 82(Suppl 3): e59-e69.
[16]	Coskun M, Salem M, Pedersen J, et al. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease[J]. Pharmacol Res, 2013, 76: 1-8.
[17]	Okabe N, Fujiwara M, Tachibana K, et al. STAT3 activation in thymic epithelial tumors: correlation with cyclin D1, JAK3, and clinical behavior[J]. Gen Thorac Cardiovasc Surg, 2021, 69(11): 1482-1491.

Please choose a citation manager

Content to export